The addition of perifosine, an AKT inhibitor, to imatinib showed a minimal activity in 40 imatinib-resistant GIST patients, but 4/5 (80%) patients with WT GIST experienced 1 partial response and 3 had stable disease according to Choi's criteria [33]. This evidence concerns the gene AKT1 and gastrointestinal stromal tumor.